Aptalis Pharma

Actavis to divest Pharmatech to TPG

Wednesday, February 18, 2015

Actavis, headquartered in Dublin, and TPG, a global private investment firm, have entered into definitive agreements under which Actavis will divest to TPG the business currently known as Aptalis Pharmaceutical Technologies (Pharmatech)—a pharmaceutical outsourcing and R&D business operating in the U.S., Canada and Europe (where the transaction is, in certain jurisdictions, still subject to local regulations, discussions and clearances). No other Aptalis businesses or products are included in the transaction. Financial terms have not been disclosed. 

[Read More]